Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Abroad (travel likely)RecruitingPHASE1
Conditions
Obesity
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Altasciences Clinical LA, Inc., Cypress, California, United States
Study leads
Clinical Transparency (dept. 2834)
Study Director
Novo Nordisk A/S